Regeneron Pharmaceuticals, Inc. (REGN) Q2 2019 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.23%

Regeneron Pharmaceuticals reported a better-than-expected EPS, which contributed to a slight increase in the stock price by 0.23%. The company did not disclose revenue figures or future guidance, leaving investors with limited insights on long-term performance. The positive EPS surprise suggests that the company is managing its costs effectively and performing well in its core areas.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$6.02	N/A	+12.13%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook based on current product performance. However, they did not provide specific guidance for future quarters.

Management highlighted the strong performance of their key products.

They expressed confidence in their ongoing research and development efforts.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.23%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.23%

Key numbers

Management commentary